Nindalieva 150mg Wholesale Price USA | Pulmonary Fibrosis Meds Supplier | Ernest Oncology

Global Exporter & Bulk Supplier: Nindalieva 150mg Capsule

🌍 Market Overview

Are you trying to establish a reliable, international commercial supply chain for advanced specialty therapies? Ernest Oncology (the premier specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd.) is a trusted global exporter, wholesale bulk supplier, and distributor of Nindalieva 150mg Capsules.

Through our verified, fully integrated international pharmaceutical distribution infrastructure, we execute consistent, high-capacity export logistics to supply Nintedanib 150mg directly to global hospital groups, specialized respiratory and cancer clinics, international pharmacy chains, and institutional procurement networks across the USA, UK, Australia, and South Africa.

🔬 Product Profile: Nindalieva 150mg Capsule

Nindalieva 150mg contains Nintedanib, a highly potent small-molecule multi-tyrosine kinase inhibitor (TKI) and anti-fibrotic agent. It works by targeting specific cellular receptors involved in signaling pathways that drive critical disease processes in both pulmonology and oncology.

Active Ingredient: Nintedanib (150mg)
Formulation Type: Soft Gelatin Capsules
Mechanism of Action: Nindalieva 150mg simultaneously binds to and blocks three vital cell surface receptors: Vascular Endothelial Growth Factor Receptors (VEGFR 1-3), Fibroblast Growth Factor Receptors (FGFR 1-3), and Platelet-Derived Growth Factor Receptors (PDGFR alpha and beta). By blocking these pathways, it down-regulates fibroblast proliferation, halts tissue scarring, reduces ongoing fibrotic processes, and inhibits the angiogenesis (blood vessel growth) required for tumor cell survival.
Primary Clinical Indications:
- Idiopathic Pulmonary Fibrosis (IPF): Prescribed to slow down the progressive decline of lung function by reducing structural scarring and swelling within pulmonary tissues, effectively delaying the long-lasting damage of IPF.
- Progressive Phenotype Interstitial Lung Diseases (PF-ILD): Indicated for chronic fibrosing interstitial lung diseases with a progressive phenotype to manage systemic tissue thickening.
- Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Formulated to reduce the rate of lung fibrosis associated with systemic sclerosis.
- Non-Small Cell Lung Cancer (NSCLC): Utilized in specific oncology combination regimens to target tumor pathways and help halt the multiplication or systemic spread of malignant cells.
Administration Protocol: Capsules must be taken with meals, spaced approximately 12 hours apart, and swallowed whole with water. They should not be crushed, chewed, or opened.

📦 Logistics & Sourcing Capabilities

Compliant Supply Lines: Sourced directly from fully verified manufacturing lines operating under rigorous global Good Manufacturing Practice (GMP) standards.
Streamlined International Export: Specialized global logistics protocols engineered to handle strict customs protocols, temperature-sensitive shipping lanes, and strict regulatory import pathways within the USA, UK, Australia, and South Africa.
Institutional Sourcing Power: Fully prepared to fulfill high-volume wholesale requirements, institutional contracts, and government tenders for national health system operators.
B2B Documentation Suite: Every container is dispatched with an export dossier containing validated Certificates of Analysis (COA), export invoice clearances, and tracking documentation.

PRESCRIPTION MEDICINE IS: YES

⚠️ Disclaimer

Nindalieva 150mg Capsule is a high-potency, targeted prescription medication. It must strictly be administered under the direct supervision, guidance, and ongoing monitoring of a registered medical oncologist, clinical hematologist, or specialized pulmonologist. This content is structured exclusively for international B2B trade, professional purchasing networks, and global wholesale pharmaceutical distribution; it does not replace professional medical advice.